EMA’s EudraVigilance ecosystem is often discussed in technical terms — electronic reporting, ICSR formats, EVWEB access, registration — but there is an equally important compliance message embedded in how the system is managed. EMA says it offers training to support stakeholders in meeting their pharmacovigilance obligations when using EudraVigilance, and it adds that training is important so users understand system functionality and submit high-quality data that support adequate monitoring of medicine safety in the EU.
EMA’s electronic-reporting page goes further: it says at least one user per organisation should be trained using EudraVigilance, and that after successful completion of training, users can register with the system. That is a strong signal that competence is not treated as optional background knowledge. It is part of the operating model.
For inspections and compliance teams, that matters a great deal. In regulated environments, system access alone is not evidence of control. A company may have a validated platform, documented procedures, and the right roles on paper, but if users are not properly trained to apply reporting standards, manage workflows, and submit quality data, the integrity of the whole process is weakened. EMA’s training structure reflects that reality.
The value of training becomes even clearer when you look at the detail of EMA’s 2026 hands-on training agenda. The course objectives include applying the ISO/ICH E2B(R3) format and rules, handling initial and follow-up reports, amendment and nullification reports, literature and parent-child cases, and reports from interventional and non-interventional studies. Those are not superficial competencies. They are directly tied to data quality, reporting correctness, and compliance performance.
Seen that way, training functions as a compliance control. It reduces the risk of submission errors, inconsistent case handling, avoidable follow-up mistakes, and misunderstandings about reporting rules. It also creates a stronger foundation for internal oversight because trained users are more likely to understand not only how to use the system, but why certain reporting behaviors matter. That conclusion is an inference, but it is strongly supported by EMA’s description of training as part of meeting pharmacovigilance obligations.
For companies preparing for audits or inspections, this should prompt a useful question: do we treat PV training as evidence of operational control, or as a box-ticking exercise? The answer can make a real difference when regulators ask how system competence is maintained and evidenced.
Why this matters for PV professionals
EMA’s EudraVigilance training framework shows that competence is part of compliance. In pharmacovigilance, training is not peripheral to quality. It is one of the mechanisms that helps protect it.
0 Comments